Why Tirzepatide Is Changing Obesity Medicine in NJ Clinics
Transforming Obesity Treatment Paradigms in New Jersey: The Emergence of Tirzepatide The landscape of obesity medicine in New Jersey clinics is undergoing a profound shift with the introduction of tirzepatide, a novel dual GIP and GLP-1 receptor agonist. Unlike traditional weight-loss interventions, tirzepatide leverages synergistic incretin hormone pathways to achieve unprecedented fat loss and metabolic … Read more